Full 2L QBank
Pharmacology General pharmacology a07c31a4

Secukinumab is

A
Anti IL 1
B
Anti IL 6
C
Anti IL 17
D
Anti IL 23
High-Yield Explanation
Ustekinumab (anti-IL-12/23) and secukinumab (anti-IL-17) monoclonal antibodies have shown promising efficacy in clinical trials, but have not yet been approved for use in Ankylosing Spondylitis. Reference: Harrison&;s Principles of Internal Medicine; kd tripathi 9th ed
← Previous Question Next Question →

Related Pharmacology MCQs

Which of the following is glucocoicoid synthesis inhibitor?
General
At a high altitude of 3000 m, a person complains of breathlessness. All of the following can...
General
All of the following drugs act on cell membrane except:
General
A non-competitive inhibitor of an enzyme?
General
Which of the following is a phase I metabolic reaction?
General
Explore All Pharmacology Questions →

Practice 2,00,000+ NEET PG Questions Free

Timed mock tests, mistake queue analytics, audio lectures & zero attempt limits on i❤️Exams.

Start Free Mock Test Now